Dyne Therapeutics reported a second-quarter GAAP loss of $1.08 per share, missing analyst estimates by $0.33. The company held cash, cash equivalents, and marketable securities of $898.5 million as of June 30, 2026. In July 2026, Dyne completed an underwritten public offering of 21,045,000 shares of common stock, generating estimated net proceeds of approximately $405.0 million. Management expects that its June 30 cash position combined with the offering proceeds will be sufficient to fund operations into the second quarter of 2028.
Dyne Therapeutics IncQ2 GAAP EPS of -$1.08 missed estimates by $0.33, indicating worse-than-expected financial performance.